Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

What will Eli Lilly do with all its cash from Mounjaro and Zepbound? What does CEO Dave Ricks think it would take for the company to reach a $1 trillion market capitalization? And how does Ricks ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, even if there were reasons for ...

CEO David Ricks said the company expects to produce 60% more doses of the drugs in the first half of 2025 compared to last year. Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered ...

That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results,” said Eli Lilly Chair and CEO David A. Ricks. “We continued to make progress on our ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... as additional proof that this is not a demand problem. According to CEO David Ricks, while the U.S. incretin market did grow 45% versus the ...

citing Eli Lilly's CEO David Ricks. Drugmakers will ask US government to pause drug price negotiations, Bloomberg News reports U.S. drugmaker Pfizer is going "all in" to develop its experimental ...

The only stock to drag more on the market was Eli Lilly, which fell 6.6% after saying it expects to report weaker revenue for the last three months of 2024 than previously forecast. CEO David Ricks ...